Kymera Therapeutics Inc Forecast, price target & analysts
Kymera Therapeutics Inc Target price 2024 - Analyst rating & recommendation
Kymera Therapeutics Inc Classifications & Recommendation:
Kymera Therapeutics Inc Target price
| Target price | $52.00 |
| Course | $30.22 |
| Price potential |
72.07%
register free of charge
|
| Number of estimates | 14 |
|
14 Analysts have issued a price target Kymera Therapeutics Inc 2025 .
The average Kymera Therapeutics Inc target price is $52.00.
This is
72.07%
register free of charge
$112.00
270.62%
register free of charge
$30.00
0.73%
register free of charge
|
|
| A rating was issued by 16 analysts: 11 Analysts recommend Kymera Therapeutics Inc to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst estimates: Analysts believe that the Kymera Therapeutics Inc share has an average upside potential 2025 of
72.07%
register free of charge
|
Sales and margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Million $ | 78.59 | 52.19 |
| 67.82% | 33.59% | |
| EBITDA margin | -206.09% | -393.68% |
| 39.02% | 91.02% | |
| Net margin | -196.72% | -361.42% |
| 47.68% | 83.72% |
16 Analysts have issued a sales forecast Kymera Therapeutics Inc 2024 . The average Kymera Therapeutics Inc sales estimate is
This results in the following potential growth figures:
4 Analysts have issued an Kymera Therapeutics Inc EBITDA forecast 2024. The average Kymera Therapeutics Inc EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
6 Kymera Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Kymera Therapeutics Inc net profit estimate is
This results in the following potential growth figures and future net margins:
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share $ | -2.52 | -3.07 |
| 12.20% | 21.83% | |
| P/E ratio | negative | |
| EV/Sales | 27.22 |
6 Analysts have issued a Kymera Therapeutics Inc forecast for earnings per share. The average Kymera Therapeutics Inc <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2024, the Kymera Therapeutics Inc share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
Kymera Therapeutics Inc...
Discover more stocks with a high price target
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.
